Multiple myeloma and cardiovascular risk (a literature review)

Samura, B. B.; Panasenko, M. O.; Dotsenko, S. Ya.

doi:10.14739/2409-2932.2020.3.216234

Current Issues in Pharmacy and Medicine: Science and Practice

2020

DOI: 10.14739/2409-2932.2020.3.216234

|View full text |Cite

Multiple myeloma and cardiovascular risk (a literature review)

B. B. Samura

M. O. Panasenko

S. Ya. Dotsenko

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Слід зазначити, що введення інгібіторів протеасом, таких як бортезоміб та карфилзоміб, теж підвищує ризик розвитку ІМ, хоча й меншою мірою, ніж імуномодуляторні засоби [14]. Кортикостероїдні препарати прямо не пов'язані зі значущою кардіоваскулярною токсичністю, але їх пролонговане застосування асоціюється із затримкою рідини, розвитком ЦД2 типу та артеріальною гіпертензією, які, у свою чергу, підвищують кардіоваскулярний ризик [15].…”

unclassified

Acute Myocardial Infarction During VRD Chemotherapy in a Patient With Multiple Myeloma: A Clinical Case

Ostrovskyi

2024

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

Acute myocardial infarction is a critical condition associated with significant morbidity and mortality rates. Myocardial infarction-related acute myocardial injury is characterized by a rapid elevation and subsequent decline in cardiac troponin concentration. According to the relevant data patients with multiple myeloma are in a high-risk category for venous and arterial thrombosis. Therefore, the incidence of cardiovascular complications, which include myocardial infarction, in these patients is higher than in the general population. The development of metaplastic anemia further compounds this risk by diminishing myocardial oxygen supply. Moreover, chemotherapy for oncohematological diseases carries the potential for cardiotoxic cardiovascular complications. Immunomodulator drugs like Thalidomide and Lenalidomide, frequently utilized in multiple myeloma treatment, have been associated with Lenalidomide-induced myocardial infarction—a prevalent adverse effect. The use of proteasome inhibitors such as Bortezomib and Carfilzomib poses an increased risk for myocardial infarction development. This clinical case presents an instance of acute myocardial infarction in a multiple myeloma patient during low cumulative chemotherapy dosage, comprising Lenalidomide and Bortezomib. It underscores the necessity for enhanced clinical, instrumental, and laboratory monitoring before each specific chemotherapy course in high-risk multiple myeloma patients. Such monitoring facilitates the early detection of chemotherapy-induced cardiotoxic effects, allowing for timely intervention and management.

show abstract

unclassified

Acute Myocardial Infarction During VRD Chemotherapy in a Patient With Multiple Myeloma: A Clinical Case

Ostrovskyi

2024

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Multiple myeloma and cardiovascular risk (a literature review)

Cited by 1 publication

References 29 publications

Acute Myocardial Infarction During VRD Chemotherapy in a Patient With Multiple Myeloma: A Clinical Case

Acute Myocardial Infarction During VRD Chemotherapy in a Patient With Multiple Myeloma: A Clinical Case

Contact Info

Product

Resources

About